logo
Share SHARE
FONT-SIZE Plus   Neg

Eli Lilly Says FDA Approved Alzheimer's Diagnostic Agent Amyvid

Eli Lilly and Company (LLY) on Friday said the Food and Drug Administration (FDA) has approved Amyvid, a radioactive diagnostic agent for use in patients being evaluated for Alzheimer's Disease and other causes of cognitive decline.

Amyvid or florbetapir F 18 injection is a molecular imaging agent under investigation for the Positron Emission Tomography imaging of beta-amyloid plaque in the brains of Alzheimer's disease patients.

A negative Amyvid scan indicates sparse-to-no amyloid plaques are present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease.

A positive scan indicates moderate to frequent amyloid plaques are present. This amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.

Amyvid was a lead candidate of Avid Radiopharmaceuticals, which became a wholly owned subsidiary of Lilly through its acquisition by the Indianapolis, Indiana-based health care giant in December 2010.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swedish music streaming app Spotify says that Apple has rejected an update of its iOS app. One of the top marketing executives of Chipotle Mexican Grill Inc., Mark Crumpacker, was put on administrative leave after he was indicted as part of a cocaine drug ring bust in New York. Crumpacker, Chipotle's chief creative and development officer, is reportedly one of the eighteen alleged buyers of cocaine indicted in the drug ring. Dell Inc. decided to end its Venue brand Android tablets and will focus on Windows 10 2-in-1 devices. There will be no operating system upgrades for Venue, however it will continue active warranty and service contract.
comments powered by Disqus
Follow RTT